Liposome Formulation for Wnt Inhibitor Delivery via Concentration Gradient
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The passive loading method for pharmaceuticals into liposomes has low encapsulation efficacy due to limitations in lipid solubility or water solubility, hindering the clinical investigation of Wnt signal pathway inhibitors as novel tumor treatments due to toxicity concerns.
Innovation Solution
A liposome formulation is prepared by mixing an aqueous solution of a Wnt signal pathway inhibitor with an alcoholic solution of lipid molecules, using a concentration gradient to encapsulate the inhibitor, with specific lipid and solubilizing agents like β-cyclodextrin, achieving high encapsulation efficiency and reduced toxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If passive loading method is used to load pharmaceuticals into liposomes, then the method is simple and widely applicable, but the encapsulation efficacy is low due to limitations in lipid solubility or water solubility
Solution Approach 1:
The patent changes the physical-chemical parameters of the loading process by using active loading methods involving pH gradients, ammonium salt concentration gradients, and temperature cycles. These parameter changes enable high encapsulation efficacy for Wnt signal pathway inhibitors that cannot be achieved by passive loading due to solubility limitations.
Solution Approach 2:
The patent applies preliminary action by pre-forming blank liposomes with established concentration gradients before introducing the pharmaceutical. The liposomes are pre-loaded with ammonium salts to create a concentration gradient that drives subsequent drug encapsulation, separating the liposome formation from the drug loading steps.
2Reliability
If Wnt signal pathway inhibitors are used for tumor treatment, then the therapeutic effect is significant, but the toxicity of the inhibitors hinders further clinical investigation
Solution Approach 1:
The patent uses liposomes as an intermediary delivery vehicle between the Wnt signal pathway inhibitor and the tumor tissue. The liposome encapsulates the inhibitor, protecting it from premature degradation and controlling its release, thereby maintaining therapeutic efficacy while reducing systemic toxicity through targeted delivery.
Solution Approach 2:
The patent applies local quality by enabling high concentrations of the Wnt signal pathway inhibitor to be delivered specifically to tumor tissues through liposomal encapsulation. The concentration gradient within the liposome ensures high local drug concentration at the target site while maintaining lower systemic concentrations, thus achieving therapeutic effect with reduced toxicity.
3Quantity of substance
If high concentration of Wnt signal pathway inhibitor is delivered to tumor tissues, then the anti-tumor effect is enhanced, but the toxicity concerns increase
Solution Approach 1:
The patent segments the drug delivery system into liposomal carriers that can be functionalized with targeting moieties. This segmentation allows the drug to be delivered in a controlled manner to specific tumor cells, achieving high local concentration while minimizing exposure to healthy tissues, thus reducing overall toxicity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The liposome formulation effectively delivers Wnt signal pathway inhibitors to tumor tissues with enhanced concentration and reduced toxicity, demonstrating superior anti-tumor effects compared to oral formulations.
Implementation Method 1
encapsulate the inhibitor, with specific lipid and solubilizing agents like β-cyclodextrin, achieving high encapsulation efficiency
Implementation Method 2
a solubilizing agent is added to the aqueous solution of the Wnt signal pathway inhibitor and then the blank vesicles upon dialysis are mixed with the aqueous solution of the Wnt signal pathway inhibitor containing the solubilizing agent
Data Source
AI summary
A liposome formulation for delivery of Wnt signal pathway inhibitor is provided herein, which comprises lipid molecules and Wnt signal pathway inhibitor, wherein the liposome formulation is prepared through following steps: (1) providing an aqueous solution of the Wnt signal pathway inhibitor and providing an alcoholic solution of the lipid molecules, (2) mixing the aqueous solution of the Wnt signal pathway inhibitor and the alcoholic solution of the lipid molecules, (3) removing alcohol solvent to obtain the liposome formulation with Wnt signal pathway inhibitor encapsulated therein.